Sinceri Senior Living Expands Reach With Addition of the Magnolia Springs Communities

May 28, 2024 9:00 AM

VANCOUVER, WA / ACCESSWIRE / May 28, 2024 / Sinceri Senior Living, a distinguished senior living management company, is thrilled to announce the addition of seven new locations, The Magnolia Springs communities. Nestled in the heart of the Ohio Valley, these communities in Kentucky, Indiana, and Ohio offer unparalleled Assisted Living and Memory Care options tailored to meet the diverse needs of their residents. "We are delighted to welcome The...

Read more

Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea

May 28, 2024 8:30 AM

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of a third-party, investigator-initiated study of crofelemer, Napo's novel plant-based prescription drug, show that twice daily oral administration of crofelemer led to a statistically meaningful reduction of abdominal pain and discomfort and improved stool consistency in functional diarrhea patients when compared to...

Read more

Towards a Gender Just Future

May 28, 2024 8:15 AM

NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 / CARE CARE has supported 16.5 million women and girls to increase their empowerment & gender equality since 2015. What do we mean by this? More girls and women are speaking out about the issues that affect them, making decisions about their homes and family as equals with their partners, working together for change in their communities, accessing services which meet their needs, and so much more.At...

Read more

Rehab.com Study Finds Southern States Rank Worst in Nation for Drug Abuse & Addiction

May 28, 2024 8:00 AM

NEW YORK, NY / ACCESSWIRE / May 28, 2024 / Five Southern states rank as the worst in the nation for drug and alcohol addiction, overdoses, deaths, and drug-involved crimes and narcotics violations, according to a new study by Rehab.com. Drug Addiction By State The new report provides a detailed look at the complex landscape of drug and alcohol use, including the effects of marijuana, cocaine, methamphetamine, heroin and fentanyl."All Americans...

Read more

NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model

May 28, 2024 8:00 AM

ZÜRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced promising results from its preclinical study KO-874 at the American Society of Clinical Psychopharmacology (ASCP) in Miami. This study evaluated the neuroprotective...

Read more

FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication

May 28, 2024 8:00 AM

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today confirms the submission of a clinical trial protocol to assess the safety and efficacy of Unbuzzd™ in healthy volunteers (METAL-2 trial). The clinical trial protocol was submitted for review and approval by the...

Read more

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

May 28, 2024 7:20 AM

CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced dosing of the first participant in a Phase 2 study of the multivalent seasonal influenza vaccine candidate developed in collaboration with GSK. The study will assess targeted optimizations for improved immune responses of the vaccine candidate against the...

Read more

Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics

May 28, 2024 7:20 AM

Partnership expands spectrum of Secarna's capabilities for the development of targeted ASOs beyond antibodies and sugar moleculesNew platform capabilities extend the reach of Secarna's antisense approaches, potentially offering new treatment options for a wider range of diseasesMARTINSRIED, GERMANY and OXFORD, UK / ACCESSWIRE / May 28, 2024 / Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery...

Read more

Q1 Interim Report January-March 2024

May 28, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / May 28, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) Press release: Stockholm, 28 May 2024. PMD Device Solutions AB's (PMDS) interim report for January - March 2024 is now available on the company's website, www.pmd-solutions.com.Financial information January - March 2024 (figures in brackets relate to the same period in Q1 2023)Consolidated net sales are in line with expectations at kSEK 11,059 (12,037). The...

Read more

Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington’s Disease

May 28, 2024 1:50 AM

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has announced the extension of its 20-year collaboration with CHDI Foundation, Inc. ("CHDI"). CHDI is a privately funded nonprofit biomedical research organisation exclusively dedicated to collaboratively developing therapeutics that will substantially improve the lives of those affected by Huntington's disease. The collaboration will further our fundamental...

Read more

IRLAB Presents at Redeye Growth Day 30 May

May 28, 2024 1:20 AM

GOTHENBURG, SE / ACCESSWIRE / May 28, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 28, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) - a company discovering and developing novel treatments for Parkinson's disease - announces today that Gunnar Olsson, CEO, will present the company on Redeye Growth Day in Stockholm on Thursday, May 30. Gunnar Olsson, CEO of IRLAB, will give a short presentation and...

Read more

Cloud DX Will Report First Quarter 2024 Results on May 30, 2024. Company will also extend the closing date of previously announced Private Placement

May 27, 2024 7:30 PM

KITCHENER, ON / ACCESSWIRE / May 27, 2024 / Cloud DX (TSXV:CDX)(OTCQB:CDXFF), will post its Q1-2024 financial results after market close on Thursday May 30, 2024.At 2:00 pm EDT on May 31, 2024 CEO Robert Kaul will host an online Earnings Call to discuss financial results to March 31, 2024 as well as recent events of interest to investors."Cloud DX is looking forward to announcing and discussing first quarter 2024 financials and further progress...

Read more

PMD Device Solutions AB (Publ) Postpones the Annual General Meeting

May 27, 2024 2:30 PM

STOCKHOLM, SWEDEN / ACCESSWIRE / May 27, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) PMD Device Solutions AB (publ) cancels the annual general meeting due to administrative reasons and hereby convenes a new annual general meeting, to be held on 28 June 2024. The notice of the meeting follows in full below. There have been no changes to the notice from the previously issued notice other than dates to align with the new AGM date.NOTICE OF...

Read more

IRLAB Appoints Kristina Torfgård as New CEO

May 27, 2024 2:20 AM

GOTHENBURG, SE / ACCESSWIRE / May 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 27, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) - a company discovering and developing novel treatments for Parkinson's disease - announces today that its Board of Directors has appointed Kristina Torfgård as the new Chief Executive Officer. She will take up the position on August 1, succeeding Gunnar Olsson who thereafter...

Read more

FSD Pharma Provides Corporate Update

May 24, 2024 5:15 PM

TORONTO, ON / ACCESSWIRE / May 24, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it has entered into an investor relations services agreement with IR Agency LLC (the "Agency") effective May 22, 2024.Pursuant to the agreement, the Agency has agreed to communicate...

Read more

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq

May 24, 2024 5:00 PM

ZÜRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that on May 22, 2024, the Company received an additional staff determination letter (the "Letter") from the staff (the...

Read more

Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q

May 24, 2024 4:30 PM

Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that on May 21, 2024, it received an additional delinquency letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying...

Read more

Asia Green Biotechnology Corp. Announces Filing of Financial Statements on SEDAR

May 24, 2024 4:15 PM

Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024, April 26, 2024, May 8, 2024, and May 10, 2024, the Company has filed the following continuous disclosure documents (collectively, the "Documents") on SEDAR:the Company's Annual Audited Financial Statements for the year ended December 31, 2023, as required by section 4.2 of National Instrument 51-102 -...

Read more

KERATO Leads with Permanent Eye Color Change: A Milestone in Cosmetic Safety

May 24, 2024 3:30 PM

KERATO, the pioneering leader in permanent eye color change, is revolutionizing the field of cosmetic ophthalmology with a groundbreaking focus on safety and efficacy. As the first and exclusive practice in the United States to specialize in safe cosmetic eye color changes, KERATO, under the leadership of Dr. Alexander Movshovich, offers unparalleled expertise and results.Transformative Reasons for Eye Color ChangeKERATO addresses a variety of...

Read more

Meet the Amazon Women of the Ivory Coast Who Are Revolutionizing Finance

May 24, 2024 3:30 PM

NORTHAMPTON, MA / ACCESSWIRE / May 24, 2024 / CAREThe "Amazons" of the Kingdom of Dahomey were known for their bravery, their audacity, and their innovation. The 18th-century Amazons challenged archetypes, stimulated debates, revolutionized gender roles, and contributed to the advancement of women's rights. Like their ancestral sisters in Dahomey, the Amazons of Côte d'Ivoire are modern-day warriors.Instead of using the implements of war to...

Read more